OIG subpoenas United Therapeutics paperwork

Share this article:

The Office of the Inspector General (OIG) of the Department of Health and Human Services is taking a gander at United Therapeutics and its marketing practices. The drugmaker announced Monday that the government agency subpoenaed  “documents regarding...the company's marketing practices relating” to its drugs Remodulin, Tyvaso and Adcirca. All are used to treat pulmonary arterial hypertension (PAH).

The "About Us" section of the OIG's website notes that the HHS Office of the Inspector General is the federal government's largest Office of Inspector General department, and is responsible for sussing out waste, fraud and abuse in HHS programs, which include Medicare and Medicaid, among others.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Janssen recruits Debbie Allen for T2 Diabetes

Actress, choreographer and "So You Think You Can Dance" judge Debbie Allen has signed on to participate with the drugmaker's type 2 diabetes awareness and wellness program.

Pfizer seeks wider Xeljanz indication

The company expects to file an sNDA for plaque psoriasis next year.

Recalls dent Stryker Q1 earnings

Sales rose 5% compared to the same period last year.